We are glad to have been selected by the distinguished symposium sponsors to present what we believe will be a very well-received rapid AST solution to the wide audience present at IDWeek.
MOUNTAIN VIEW, Calif. (PRWEB) June 06, 2019
Specific Diagnostics has been invited to present its Reveal Rapid AST system at a symposium entitled “Rapid Diagnostics and Resistance: Making Sense of Now and the Future Part 1 – Rapid Phenotypic AST Methods” at IDWeek October 4, in Washington, DC.
“Specific welcomes this opportunity to share information about the Reveal instrument which by this time will be in clinical trials in Europe,” said Paul A. Rhodes, Ph.D., Specific Diagnostics CEO. “We are pleased that the symposium committee extended this invitation.”
Specific’s Reveal instrument furnishes phenotypic MIC directly from a positive blood culture sample or isolate dilution in an average of 4.5 hours. It can be paired with any FDA-cleared rapid ID solution to provide the combined AST/ID results that hospitals need to take action to select drug for those patients with time-sensitive infections. Reveal’s simple 2-minute sample preparation workflow is entirely comparable to that of legacy AST methods, with a very broad drug menu fully comparable to that of legacy systems. The modular Reveal instruments accommodate the sample throughput to comfortably process all positive bloods and urgent isolates produced in large labs daily, all at what will be industry leading affordability consistent with very broad adoption.
“We will be demonstrating Reveal at our exhibit at ASM in San Francisco June 21-24, and look forward to continuing our engagement with early-evaluation customers in the coming months,” said Ray Martino, COO. “We are glad to have been selected by the distinguished symposium sponsors to present what we believe will be a very well-received rapid AST solution to the wide audience present at ID Week. Our customers want same-shift AST for their time-sensitive samples, and Reveal delivers this capability at a cost that will prompt wide consideration.”
About Specific’s Product Family
Specific’s products utilize inexpensive printed chemical sensor arrays to obtain a fingerprint that combines detection of growth, antibiotic efficacy and microorganism ID into simple, automated, low cost instruments and disposables. Reveal’s accuracy reflects that accuracy of gold standard broth microdilution methods, but with results obtained within an average of 4.5 hours of a positive blood culture, directly from a diluted positive blood sample, as well as from isolate dilutions. The system will streamline lab work flow, reduce costs, and substantially shorten the time from sample arrival to selection of effective therapy, saving patients faced with fast moving and deadly drug resistant infections.
About Specific Diagnostics
Specific Technologies has developed in vitro diagnostic systems for the detection and identification of microorganisms while they grow in culture. The company’s unique, patented metabolomic signature technology leverages a low-cost printed chemical sensor array, enabling diagnostic products that simplify workflow and speed time-to-answer at low cost. Specific is located in Mountain View, CA.